The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients
暂无分享,去创建一个
[1] M. Marescotti,et al. Optimized glycaemic control achieved with add‐on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine , 2011, Diabetes, obesity & metabolism.
[2] J. Holst,et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. , 2011, Endocrinology.
[3] J. Holst,et al. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs , 2011, Diabetologia.
[4] J. Kaufman,et al. Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome , 2011, Diabetes.
[5] J. Teixeira,et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase‐4 activity in obese patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.
[6] B. Charbonnel,et al. Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies , 2011, Diabetes, obesity & metabolism.
[7] S. Patterson,et al. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.
[8] Yup Kang,et al. Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. , 2010, Diabetes research and clinical practice.
[9] J. Féher,et al. Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker , 2010, PloS one.
[10] A. Avogaro,et al. The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.
[11] S. Patterson,et al. Investigation of the effect of oral metformin on dipeptidylpeptidase‐4 (DPP‐4) activity in Type 2 diabetes 1 , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[12] K. Tsuda,et al. GLUCOSE REGULATION OF DIPEPTIDYL PEPTIDASE IV GENE EXPRESSION IS MEDIATED BY HEPATOCYTE NUCLEAR FACTOR‐1α IN EPITHELIAL INTESTINAL CELLS , 2008, Clinical and experimental pharmacology & physiology.
[13] J. Lindsay,et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. , 2008, Diabetes research and clinical practice.
[14] J. A. Davis,et al. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice. , 2007, Life sciences.
[15] Sten Madsbad,et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. , 2006, European journal of endocrinology.
[16] J. Holst,et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.
[17] P. Flatt,et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[18] E. Mannucci,et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus , 2005, Diabetologia.
[19] J. Lenhard,et al. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. , 2004, Biochemical and biophysical research communications.
[20] Y. S. Kim,et al. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. , 1992, The Journal of biological chemistry.
[21] N. Thompson,et al. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. , 1991, The Biochemical journal.